EP
BVS icon

Eversept Partners’s Bioventus BVS Stock Holding History

Eversept Partners’s Portfolio BVS Stock Details BVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-159,110
Closed -$1.45M – 124
2026
Q1 		$1.45M Sell
159,110
-312,147
-66% -$2.62M 0.08% 98
2025
Q4 		$3.51M Buy
471,257
+37,324
+9% +$268K 0.18% 79
2025
Q3 		$2.9M Buy
+433,933
New +$3.01M 0.2% 59

Other funds holding BVS

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
JIC
Juniper Investment Company New York $378M AUM 95.37% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Eversept Partners's BVS Position: Q2 2026 in Review

Eversept Partners sold out of Bioventus (BVS) in Q2 2026, closing a stake of 159,110 shares — an estimated $1.45M sold.

Eversept Partners first reported a position in BVS in Q3 2025 and held it in 3 quarters. The position peaked at $3.51M in Q4 2025. 157 funds tracked by Wall St. Rank hold BVS as of Q2 2026.

  • Eversept Partners reported no remaining Bioventus position as of Q2 2026 after selling out during the quarter.
  • Eversept Partners sold 159,110 Bioventus shares in Q2 2026, an estimated $1.45M.
  • Eversept Partners first reported a position in Bioventus in Q3 2025 and held it in 3 quarters.
  • Eversept Partners's Bioventus position peaked at $3.51M in Q4 2025.
  • 157 funds tracked by Wall St. Rank held Bioventus as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.